CEACAM5 and neoplasm: For analysis of correlative studies, the cases were divided in two clinical groups including patients who had clinical benefit as defined by CEA reduction, minor radiographic tumor regression by RECIST v1.1 (>10%) and prolonged SD by RECIST v1.1 (≥100 days), and those who did not experience clinical benefit (e.g., progressive disease).